Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis
- 1 September 2016
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 116 (11) , 987-997
Abstract
Endocannabinoids modulate atherogenesis by triggering different receptors. Recently, orphan G protein-coupled receptors (GPRs) were suggested to be activated by endocannabinoids, possibly regulating vasorelaxation. Here, we investigated whether GPR55 antagonism with CID16020046 would impact on atherosclerotic size and inflammation in two mouse models of early and more advanced atherogenesis. Eleven-week old ApoE−/− mice were fed either a normal diet ([ND] for 16 weeks) or a high-cholesterol diet ([HD] for 11 weeks), resulting in different degrees of hypercholesterolaemia and size of atherosclerosis. CID16020046 (0.5 mg/kg) or vehicle were intraperitoneally administrated five times per week in the last three weeks before euthanasia. Treatment with CID1602004 was well-tolerated, but failed to affect atherosclerotic plaque and necrotic core size, fibrous cap thickness, macrophage and smooth muscle cell content as well as Th cell polarisation. In ND mice, treatment with CID1602004 was associated with increased chemokine production, neutrophil and MMP-9 intraplaque content as well as reduced collagen as compared to vehicletreated animals. In HD mice, CID1602004 increased intraplaque MMP-9 and abrogated collagen content without affecting neutrophils. In vitro, serum from CID1602004-treated ND mice increased mouse neutrophil chemotaxis towards CXCL2 as compared to serum from vehicletreated animals. CID1602004 dose-dependently induced neutrophil degranulation that was reverted by co-incubation with the GPR55 agonist Abn-CBD. In supernatants from degranulation experiments, increased levels of the endocannabinoid and putative GPR55 ligand anandamide (AEA) were found, suggesting its possible autocrine control of neutrophil activity. These results indicate that GPR55 is critical for the negative control of neutrophil activation in different phases of atherogenesis. Supplementary Material to this article is available online at www.thrombosis-online.com.Keywords
Funding Information
- European Commission (FP7-INNOVATION I HEALTH-F2–2013–602114)
- National Science Foundation (#310030_152639/1 and #IZ73Z0_152578)
This publication has 39 references indexed in Scilit:
- Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulationVascular Pharmacology, 2016
- Lysophospholipids and their G protein-coupled receptors in atherosclerosisFrontiers in Bioscience-Landmark, 2016
- The GPR55 antagonist CID16020046 protects against intestinal inflammationNeurogastroenterology & Motility, 2015
- The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011European Heart Journal, 2014
- At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunctionTrends in Pharmacological Sciences, 2012
- Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesityEuropean Heart Journal, 2011
- Cellular immunity, low-density lipoprotein and atherosclerosis: Break of tolerance in the artery wallThrombosis and Haemostasis, 2011
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Identification of GPR55 as a lysophosphatidylinositol receptorBiochemical and Biophysical Research Communications, 2007
- Low dose oral cannabinoid therapy reduces progression of atherosclerosis in miceNature, 2005